Io Biotech, Inc. rose 3.19% in after-hours trading, with the biotech sector entering a pivotal phase fueled by scientific breakthroughs, accelerated regulatory approvals, and a surge of strategic dealmaking. The Nasdaq Biotechnology Index has posted strong gains, signaling renewed investor confidence. The FDA is clearing a record number of novel therapies, while global mergers and acquisitions have climbed past $105 billion, a seven percent increase from last year.
Comments
No comments yet